1. Home
  2. PHAR vs ESQ Comparison

PHAR vs ESQ Comparison

Compare PHAR & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • ESQ
  • Stock Information
  • Founded
  • PHAR 1988
  • ESQ 2006
  • Country
  • PHAR Netherlands
  • ESQ United States
  • Employees
  • PHAR N/A
  • ESQ N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • ESQ Commercial Banks
  • Sector
  • PHAR Health Care
  • ESQ Finance
  • Exchange
  • PHAR Nasdaq
  • ESQ Nasdaq
  • Market Cap
  • PHAR 731.1M
  • ESQ 756.3M
  • IPO Year
  • PHAR N/A
  • ESQ 2017
  • Fundamental
  • Price
  • PHAR $10.00
  • ESQ $96.35
  • Analyst Decision
  • PHAR Strong Buy
  • ESQ Hold
  • Analyst Count
  • PHAR 3
  • ESQ 3
  • Target Price
  • PHAR $30.00
  • ESQ $99.00
  • AVG Volume (30 Days)
  • PHAR 3.6K
  • ESQ 171.0K
  • Earning Date
  • PHAR 07-31-2025
  • ESQ 07-24-2025
  • Dividend Yield
  • PHAR N/A
  • ESQ 0.73%
  • EPS Growth
  • PHAR N/A
  • ESQ 13.51
  • EPS
  • PHAR N/A
  • ESQ 5.27
  • Revenue
  • PHAR $320,708,000.00
  • ESQ $124,132,000.00
  • Revenue This Year
  • PHAR $13.31
  • ESQ N/A
  • Revenue Next Year
  • PHAR $7.68
  • ESQ $10.72
  • P/E Ratio
  • PHAR N/A
  • ESQ $18.32
  • Revenue Growth
  • PHAR 24.13
  • ESQ 14.72
  • 52 Week Low
  • PHAR $6.65
  • ESQ $49.16
  • 52 Week High
  • PHAR $12.61
  • ESQ $101.35
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 43.61
  • ESQ 56.40
  • Support Level
  • PHAR $9.99
  • ESQ $93.57
  • Resistance Level
  • PHAR $10.59
  • ESQ $101.28
  • Average True Range (ATR)
  • PHAR 0.35
  • ESQ 3.23
  • MACD
  • PHAR -0.14
  • ESQ 0.16
  • Stochastic Oscillator
  • PHAR 7.45
  • ESQ 58.99

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.

Share on Social Networks: